-
公开(公告)号：WO2007117465A3
公开(公告)日：2008-08-28
申请号：PCT/US2007008307
申请日：2007-04-02
Applicant: ABBOTT LAB , ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
Inventor： ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。
-
公开(公告)号：WO2003020880A3
公开(公告)日：2003-03-13
申请号：PCT/US2002/024546
申请日：2002-08-02
Applicant: ABBOTT LABORATORIES , BORHANI, David, W. , CALDERWOOD, David , DIXON, Richard, W. , HIRST, Gavin, C. , HRNCIAR, Peter , LOEW, Andreas , LEUNG, Adelaine , RITTER, Kurt
Inventor： BORHANI, David, W. , CALDERWOOD, David , DIXON, Richard, W. , HIRST, Gavin, C. , HRNCIAR, Peter , LOEW, Andreas , LEUNG, Adelaine , RITTER, Kurt
IPC: C07K14/00
Abstract: The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.
-
公开(公告)号：WO2012094623A3
公开(公告)日：2012-08-30
申请号：PCT/US2012020529
申请日：2012-01-06
Applicant: ABBOTT LAB , BORHANI DAVID W , SADHUKHAN RAMKRISHNA , LACY SUSAN E , SOUTTER HOLLY H
Inventor： BORHANI DAVID W , SADHUKHAN RAMKRISHNA , LACY SUSAN E , SOUTTER HOLLY H
IPC: C07K16/24 , A61K39/395
CPC classification number: C07K16/244 , A61K2039/505 , C07K2299/00 , C07K2317/21 , C07K2317/565 , C07K2317/73
Abstract: The present invention provides antibodies, and antigen-binding portions thereof, that bind to epitopes comprising at least one amino acid residues from residues 1-197 of the p40 subunit of IL-12 and/or IL-23. The invention further provides nucleic acids encoding the antibodies, compositions, vectors and host cells comprising the antibodies, and methods of making and using the same.
Abstract translation: 本发明提供了与包含IL-12和/或IL-23的p40亚基的残基1-197的至少一个氨基酸残基的表位结合的抗体及其抗原结合部分。 本发明还提供编码抗体，组合物，载体和包含抗体的宿主细胞的核酸，以及制备和使用该抗体的方法。
-
公开(公告)号：WO2008057240A3
公开(公告)日：2008-11-06
申请号：PCT/US2007022622
申请日：2007-10-25
Applicant: ABBOTT BIOTECH LTD , BORHANI DAVID W , FRAUNHOFER WOLFGANG , KRAUSE HANS-JUERGEN , KOENIGSDORFER ANETTE , WINTER GERHARD , GOTTSCHALK STEFAN
Inventor： BORHANI DAVID W , FRAUNHOFER WOLFGANG , KRAUSE HANS-JUERGEN , KOENIGSDORFER ANETTE , WINTER GERHARD , GOTTSCHALK STEFAN
CPC classification number: C07K16/241 , A61K9/50 , A61K39/3955 , C07K2299/00 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
Abstract translation: 本发明涉及一种用于使抗hTNFα抗体结晶的分批结晶方法，其允许以工业规模生产所述抗体; 根据所述方法获得的抗体晶体; 含有所述晶体的组合物以及所述晶体和组合物的使用方法。
-
公开(公告)号：WO2012094623A2
公开(公告)日：2012-07-12
申请号：PCT/US2012/020529
申请日：2012-01-06
Applicant: ABBOTT LABORATORIES , BORHANI, David, W. , SADHUKHAN, Ramkrishna , LACY, Susan, E. , SOUTTER, Holly, H.
Inventor： BORHANI, David, W. , SADHUKHAN, Ramkrishna , LACY, Susan, E. , SOUTTER, Holly, H.
IPC: A61K39/395
CPC classification number: C07K16/244 , A61K2039/505 , C07K2299/00 , C07K2317/21 , C07K2317/565 , C07K2317/73
Abstract: The present invention provides antibodies, and antigen-binding portions thereof, that bind to epitopes comprising at least one amino acid residues from residues 1-197 of the p40 subunit of IL-12 and/or IL-23. The invention further provides nucleic acids encoding the antibodies, compositions, vectors and host cells comprising the antibodies, and methods of making and using the same.
Abstract translation: 本发明提供了结合表位的抗体及其抗原结合部分，所述表位包含IL-12和/或IL-12的p40亚基的残基1-197的至少一个氨基酸残基， 23。 本发明进一步提供编码包含抗体的抗体，组合物，载体和宿主细胞的核酸，以及制备和使用它们的方法。
-
Patent Agency Ranking
公开(公告)号：WO2008121301A1
公开(公告)日：2008-10-09
申请号：PCT/US2008/004006
申请日：2008-03-27
Applicant: ABBOTT LABORATORIES , BORHANI, David W. , FRAUNHOFER, Wolfgang , KRAUSE, Hans-Juergen , KOENIGSDORFER, Anette , WINTER, Gerhard , GOTTSCHALK, Stefan
Inventor： BORHANI, David W. , FRAUNHOFER, Wolfgang , KRAUSE, Hans-Juergen , KOENIGSDORFER, Anette , WINTER, Gerhard , GOTTSCHALK, Stefan
CPC classification number: C07K16/244 , A61K39/39591 , C07K2299/00 , C30B7/00 , Y02A50/401
Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
Abstract translation: 本发明涉及用于结晶能够以工业规模生产抗体的抗-hIL-12抗体的分批结晶方法，根据该方法获得的抗体晶体，含有晶体的组合物，以及使用晶体和组合物的方法 。
-
公开(公告)号：WO2008057240A9
公开(公告)日：2008-08-28
申请号：PCT/US2007022622
申请日：2007-10-25
Applicant: ABBOTT BIOTECH LTD , BORHANI DAVID W , FRAUNHOFER WOLFGANG , KRAUSE HANS-JUERGEN , KOENIGSDORFER ANETTE , WINTER GERHARD , GOTTSCHALK STEFAN
Inventor： BORHANI DAVID W , FRAUNHOFER WOLFGANG , KRAUSE HANS-JUERGEN , KOENIGSDORFER ANETTE , WINTER GERHARD , GOTTSCHALK STEFAN
IPC: C07K16/24
CPC classification number: C07K16/241 , A61K9/50 , A61K39/3955 , C07K2299/00 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
Abstract translation: 本发明涉及用于结晶抗-hTNFα抗体的分批结晶方法，其允许以工业规模生产所述抗体; 根据所述方法获得的抗体晶体; 含有所述晶体的组合物以及所述晶体和组合物的使用方法。
-
公开(公告)号：WO2009020654A1
公开(公告)日：2009-02-12
申请号：PCT/US2008/009549
申请日：2008-08-08
Applicant: ABBOTT LABORATORIES , FRAUNHOFER, Wolfgang , BORHANI, David W. , WINTER, Gerhard , GOTTSCHALK, Stefan
Inventor： FRAUNHOFER, Wolfgang , BORHANI, David W. , WINTER, Gerhard , GOTTSCHALK, Stefan
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K2039/505 , C07K1/306 , C07K2299/00 , C07K2317/14 , C07K2317/54 , C07K2317/76 , C30B29/58 , Y02A50/388
Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
Abstract translation: 本发明涉及用于结晶抗人TNFα（hTNFα）抗体的分批结晶方法和允许以工业规模生产所述抗体的抗体片段; 控制抗体晶体大小的方法，例如抗hTNFα抗体片段的晶体，含有所述晶体的组合物以及使用所述晶体和组合物的方法。
-
公开(公告)号：WO2007117465A2
公开(公告)日：2007-10-18
申请号：PCT/US2007/008307
申请日：2007-04-02
Applicant: ABBOTT LABORATORIES , ERICSSON, Anna M. , BURCHAT, Andrew , FRANK, Kristine E. , CALDERWOOD, David J. , ABBOTT, Lily K. , ARGIRIADI, Maria A. , BORHANI, David W. , CUSACK, Kevin P. , DIXON, Richard W. , GORDON, Thomas D. , MULLEN, Kelly D. , TALANIAN, Robert V. , WU, Xiaoyun , ZHANG, Xiaolei , WANG, Lu X. , LI, Biqin , BARBERIS, Claude E. , WISHART, Neil
Inventor： ERICSSON, Anna M. , BURCHAT, Andrew , FRANK, Kristine E. , CALDERWOOD, David J. , ABBOTT, Lily K. , ARGIRIADI, Maria A. , BORHANI, David W. , CUSACK, Kevin P. , DIXON, Richard W. , GORDON, Thomas D. , MULLEN, Kelly D. , TALANIAN, Robert V. , WU, Xiaoyun , ZHANG, Xiaolei , WANG, Lu X. , LI, Biqin , BARBERIS, Claude E. , WISHART, Neil
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。
-
公开(公告)号：WO03020880A2
公开(公告)日：2003-03-13
申请号：PCT/US0224546
申请日：2002-08-02
Applicant: ABBOTT LAB , BORHANI DAVID W , CALDERWOOD DAVID , DIXON RICHARD W , HIRST GAVIN C , HRNCIAR PETER , LOEW ANDREAS , LEUNG ADELAINE , RITTER KURT
Inventor： BORHANI DAVID W , CALDERWOOD DAVID , DIXON RICHARD W , HIRST GAVIN C , HRNCIAR PETER , LOEW ANDREAS , LEUNG ADELAINE , RITTER KURT
CPC classification number: C12N9/1205 , C07K2299/00
Abstract: The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.
Abstract translation: 本发明涉及包含Lck的配体结合结构域，这些多肽的结晶形式的多肽以及使用这些结晶形式来确定Lck的催化结构域的三维结构。 本发明还涉及单独或与抑制剂复合的Lck催化结构域的三维结构在设计和/或鉴定潜在的Lck活性抑制剂的方法中的用途，例如抑制 天然底物到Lck催化结构域。 本发明还涉及单独或与抑制剂复合的Lck催化结构域的三维结构在设计和/或鉴定潜在的Lck活性选择性抑制剂的方法中的应用，例如抑制 选择性地将天然底物连接到Lck催化结构域。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.019 seconds)
